Fuente: FierceBiotech The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Biosciences. The flop leaves Novartis with one win and two failures from a rapid-fire run of key clinical readouts.